Tuberculosis (TB) is the second leading infectious disease killer. According to the World Health Organization, every year, more than 10 million people fall ill with TB, and 1.5 million people die from the disease. The thing is, though, that it could be worse. Not nearly everyone who is infected has TB disease. “Tuberculosis is a disease that targets a small number of infected people,” Igor Kramnik, of Boston University, told BioWorld. Read More
Researchers from Fudan University and affiliated organizations have reported the discovery of dual inhibitors of histone deacetylase (HDAC) and tubulin polymerization as potential anticancer agents. Read More
Assembly Biosciences Inc. has selected ABI-6250, an orally bioavailable small-molecule entry inhibitor, as a development candidate to progress to IND-enabling studies for the treatment of chronic hepatitis D virus (HDV) infection. Read More
Complementarity-determining regions (CDRs) are relatively short peptide loops in antibodies where they bind to their specific antigens. Bovines, unlike humans and other vertebrates, rely on ultralong CDR H3 antibody knob regions to neutralize cryptic viral epitopes. Read More
Chengdu Scimount Pharmatech Co. Ltd. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune, inflammatory, bone, cardiovascular, metabolic, neurological and respiratory disorders. Read More
Researchers from Assembly Biosciences Inc. recently presented details on the discovery and preclinical evaluation of a novel small-molecule hepatitis B virus (HBV) and hepatitis D virus (HDV) entry inhibitor, AB-1659. Read More
Sab Biotherapeutics Inc. has announced a private placement of up to $130 to fund the company’s lead research program, SAB-142, a potential disease-modifying treatment for type 1 diabetes. SAB-142 is expected to advance into clinical trials in the fourth quarter of this year. Read More
Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have synthesized cucurbitacin B derivatives acting as NF-κB activation inhibitors reported to be useful for the treatment of cancer and inflammatory disorders. Read More
Bruton tyrosine kinase (BTK) inhibition is a provenly effective strategy for the treatment of B-cell malignancies with several compounds approved such as ibrutinib, acalabrutinib or zanubrutinib. BTK also plays a central role in immunity and has thus emerged as a potential therapeutic target in autoimmune and inflammatory disorders. Read More
Sorrento Therapeutics Inc. has divulged antibody-drug conjugates comprising antibodies targeting HER2 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer. Read More
Chiesi Farmaceutici SpA has described amido cyclopropyl derivatives acting as lysophospholipid LPA1 receptor (LPAR1; EDG2) antagonists reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF). Read More
Oryzon Genomics SA has announced two grants that will support the exploration of the role of epigenetic targets in the treatment of neuronal pathologies. Funded by the Spanish State Research Agency and the Ministry of Science and Innovation, the grants cover two public-private collaboration projects. Read More
